T
Toni K. Choueiri
Researcher at Harvard University
Publications - 1230
Citations - 84800
Toni K. Choueiri is an academic researcher from Harvard University. The author has contributed to research in topics: Renal cell carcinoma & Sunitinib. The author has an hindex of 107, co-authored 1071 publications receiving 59514 citations. Previous affiliations of Toni K. Choueiri include University of Ulsan & University of British Columbia.
Papers
More filters
Journal ArticleDOI
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
Ziad Bakouny,Chris Labaki,Punita Grover,Joy Awosika,Shuchi Gulati,Chih-Yuan Hsu,Saif Alimohamed,Babar Bashir,Stephanie Berg,Mehmet Asim Bilen,Daniel W. Bowles,Cecilia A. Castellano,Aakash Desai,Arielle Elkrief,Omar Eton,Leslie A. Fecher,Daniel Blake Flora,Matthew D. Galsky,Margaret E. Gatti-Mays,Alicia Gesenhues,Michael Glover,Dharmesh Gopalakrishnan,Shilpa Gupta,Thorvardur R. Halfdanarson,Brandon Hayes-Lattin,Mohamed Hendawi,Emily Hsu,Clara Hwang,Roman Jandarov,Chinmay Jani,Douglas B. Johnson,Monika Joshi,Hina Khan,Shaheer Khan,N Knox,Vadim S. Koshkin,Amit A. Kulkarni,Daniel Kwon,Sara Matar,Rana R. McKay,Sanjay Mishra,Feras Aymen Moria,Amanda Nizam,Nora L. Nock,Taylor K. Nonato,Justin Panasci,Lauren D. Pomerantz,Andrew J. Portuguese,Destie Provenzano,Matthew Puc,Yuan James Rao,Terence Duane Rhodes,Gregory J. Riely,Jacob J Ripp,Andrea V. Rivera,Erika Ruiz-García,Andrew Schmidt,Adam J. Schoenfeld,Gary K. Schwartz,Sumit A. Shah,Justin Shaya,Suki Subbiah,Lisa May Ling Tachiki,Matthew D Tucker,Melissa Valdez-Reyes,Lisa Weissmann,Michael Wotman,Elizabeth Marie Wulff-Burchfield,Zhuoer Xie,Yuanchu J Yang,M. A. Thomson,Dimpy P. Shah,Jeremy L. Warner,Yu Shyr,Toni K. Choueiri,Trisha Wise-Draper +75 more
TL;DR: In this paper , the authors investigated the association of baseline immunosuppression and/or IO-based therapies with COVID-19 severity and cytokine storm in patients with cancer.
Journal ArticleDOI
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model as a prognostic tool in metastatic renal cell carcinoma (mRCC) patients previously treated with first-line targeted therapy (TT).
Jenny J. Ko,Wanling Xie,Daniel Y.C. Heng,Nils Kroeger,Jae-Lyun Lee,Brian I. Rini,Jennifer J. Knox,Georg A. Bjarnason,Lauren C. Harshman,Sumanta K. Pal,Takeshi Yuasa,Martin Smoragiewicz,Frede Donskov,Aristotelis Bamias,Lori Wood,D. Scott Ernst,Neeraj Agarwal,Ulka N. Vaishampayan,Sun Young Rha,Toni K. Choueiri +19 more
TL;DR: The IMDC prognostic model in patients with mRCC receiving next-line TT after progression on 1st- line TT was validated and the 3-factor-MSKCC model (Motzer et al JCO 2004) used for previously-treated patients was compared.
Journal ArticleDOI
Avelumab (MSB0010718C; anti-PD-L1) in combination with axitinib as first-line treatment for patients with advanced renal cell carcinoma.
James Larkin,Michael S. Gordon,Fiona C Thistlethwaite,Paul Nathan,Brian I. Rini,Marcella Martignoni,Michael Shnaidman,Chiara Chiruzzi,Alessandra di Pietro,Toni K. Choueiri +9 more
TL;DR: This open-label, multicenter, dose-finding study evaluates the novel combination of avelumab + axitinib as 1L therapy in pts with aRCC to assess safety and tolerability.
Journal ArticleDOI
First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
TL;DR: Each frontline treatment option for metastatic clear cell renal cell carcinoma with multiple first-line options currently available is described in detail through this review to aid the decision-making process.
Journal ArticleDOI
Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.
Cristina Sáez,Toni K. Choueiri,Mauricio Burotto,Thomas Powles,Maria T Bourlon,Amishi Yogesh Shah,Yoshihiko Tomita,Jens Bedke,Joshua Zhang,Burcin Simsek,Christian Scheffold,Bernard Escudier,Robert J. Motzer,Andrea B. Apolo +13 more
TL;DR: In CheckMate 9ER, more pts receiving N+C achieved deeper responses vs SUN, and increasingly deeper response led to better OS outcome; yet OS rates and medians were comparable between arms for CR, PR1, PR2, and PR3.